Immunomedics is a biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.
In addition, Immunomedics has also received an another two grants from the NIH. These three grants amount to $2.1 million payable by the NIH over a period of two years. One of the awards can be extended to three years with a potential $2.5 million additional funding, if certain goals and milestones are met.
Deal Type Partnership Sub-Category Other Deal Status Announced: 2009-10-19
Deal Participants
Partner 1 (Company) National Institutes of Health Partner 2 (Company) Immunomedics, Inc. Partner 3 (Company) The U.S. Department of Health and Human Services

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index